Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | $996 | 10-14 weeks |
Description | KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC 50 s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. Multiple myeloma MM1S cells treated with KDOAM-25 citrate show increased global H3K4 methylation at transcriptional start sites and impaired proliferation [1]. |
In vitro | KDOAM-25 citrate inhibits most potently KDM5B with an IC 50 of ~50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 citrate is inactive against any of the other tested JmjC family members [1]. KDOAM-25 citrate is able to reduce the viability of MM1S cells with an IC 50 of ~30 μM after a delay of 5-7 days [1]. KDOAM-25 citrate treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase [1]. KDOAM-25 citrate (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells [1]. |
Molecular Weight | 499.51 |
Formula | C21H33N5O9 |
Cas No. | 2448475-08-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 200 mg/mL (400.39 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.